Data / Drug companies / Rizatriptan benzoate
Rizatriptan benzoate: 25 companies and 65 products in the FDA NDC directory
Rizatriptan benzoate is listed in the FDA National Drug Code Directory by 25 companies, with 65 products in commercial distribution. 60 of the products (92.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, orally disintegrating; film, and the newest product started marketing on April 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 25
- Products
- 65
- Generic (ANDA) products
- 60 (92.3%)
- Application numbers
- 17
- Routes
- Oral
- Brand names
- Rizafilm, Maxalt, Maxalt-Mlt
- openFDA record search
- api.fda.gov
Companies that list rizatriptan benzoate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 7 | tablet; tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2013 |
| Aurobindo Pharma Limited | 4 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | July 1, 2013 |
| Direct_Rx | 4 | tablet; tablet, film coated | Generic drugs (ANDA) | September 11, 2023 |
| Glenmark Pharmaceuticals Inc., USA | 4 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | July 1, 2013 |
| Golden State Medical Supply, Inc. | 4 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | July 1, 2013 |
| Rising Pharma Holdings, Inc. | 4 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | July 1, 2013 |
| Unichem Pharmaceuticals (USA), Inc. | 4 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | March 7, 2017 |
| A-S Medication Solutions | 3 | tablet; film | Generic drugs (ANDA) | April 27, 2026 |
| Proficient Rx LP | 3 | tablet, orally disintegrating; tablet | Generic drugs (ANDA) | March 7, 2017 |
| Ascend Laboratories, LLC | 2 | tablet | Generic drugs (ANDA) | June 25, 2012 |
| Asclemed USA, Inc. | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2013 |
| Bionpharma Inc. | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | January 17, 2017 |
| Chartwell RX, LLC | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2013 |
| Cipla USA Inc. | 2 | tablet | Generic drugs (ANDA) | July 22, 2016 |
| Creekwood Pharmaceuticals LLC | 2 | tablet | Generic drugs (ANDA) | December 31, 2012 |
| Direct RX | 2 | tablet | Generic drugs (ANDA) | April 22, 2019 |
| Gensco Laboratories LLC | 2 | film | New drug applications (NDA) | April 27, 2026 |
| Macleods Pharmaceuticals Limited | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | September 23, 2014 |
| Organon LLC | 2 | tablet; tablet, orally disintegrating | New drug applications (NDA) | June 1, 2021 |
| Panacea Biotec Limited | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | January 17, 2017 |
| Teva Pharmaceuticals USA, Inc. | 2 | tablet | Generic drugs (ANDA) | February 12, 2013 |
| Advanced Rx of Tennessee, LLC | 1 | tablet, orally disintegrating | Generic drugs (ANDA) | October 15, 2025 |
| NuCare Pharmaceuticals,Inc. | 1 | tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2013 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | December 31, 2012 |
| Remedyrepack Inc. | 1 | tablet, orally disintegrating | Generic drugs (ANDA) | June 18, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 33 | 50.8% |
| Tablet, orally disintegrating | 28 | 43.1% |
| Film | 3 | 4.6% |
| Tablet, film coated | 1 | 1.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 60 | 92.3% |
| New drug applications (NDA) | 5 | 7.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Serotonin-1b and Serotonin-1d Receptor Agonist | 65 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.